Results 91 to 100 of about 99,201 (311)
Frailty in Hematologic Malignancy [PDF]
Current Hematologic Malignancy Reports, 2018 Older adults with hematologic malignancy are a growing demographic. Estimating risk of chemotherapy toxicity based on age alone is an unreliable estimate of quality of life, functional capacity, or risk of treatment complications.Dedicated geriatric assessment tools can aid the clinician in identifying geriatric syndromes such as frailty, resulting in ...
Thuy T, Koll, Ashley E, Rosko
openaire +2 more sources
Molecular Oncology, EarlyView.We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric +10 more
wiley +1 more source
Research and Practice in Thrombosis and Haemostasis, 2021 Background Acquired von Willebrand syndrome (AVWS) has been associated with monoclonal gammopathy of undetermined significance (MGUS), with limited data on its management. Methods We conducted a systematic literature search in Medline (Ovid), Embase, and
Mouhamed Yazan Abou‐Ismail +3 more
doaj +1 more source
Immunotherapy in hematologic malignancies: past, present, and future
, 2017 The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatment landscape for a variety of solid ...
Steven Z. Pavletic, Annie Im
core +1 more source
Molecular Oncology, EarlyView.In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera +11 more
wiley +1 more source
Expanding role of lenalidomide in hematologic malignancies
, 2015 Nilanjan Ghosh, Michael R Grunwald, Omotayo Fasan, Manisha Bhutani Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA Abstract: Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration
Bhutani M, Ghosh N, Fasan O, Grunwald MR
core
Targeting Oncogenic Drivers and Signaling Pathways in Hematologic Malignancies
, 2023 oncogenic drivers; signaling; pathways; hematologic malignancies ...
core
E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer
Molecular Oncology, EarlyView.Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov +3 more
wiley +1 more source
Advanced Science, 2020 The roles of mitochondrial dysfunction in carcinogenesis remain largely unknown. The effects of PTEN‐induced putative kinase 1 (PINK1)‐dependent mitophagy on the pathogenesis of multiple myeloma (MM) are determined.
Shengjun Fan +11 more
doaj +1 more source
Molecular Oncology, EarlyView.Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source